Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on July 28, 2021. The filing discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Helen Collins, M.D., as a Class II director, effective July 28, 2021. Her term expires at the 2022 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
There is no guidance, outlook, or management commentary regarding business operations or risks in this filing. The document details the compensatory arrangements for Dr. Collins under the Company's Non-Employee Director Compensation Policy:
- Cash Retainer: $40,000 annually for Board service.
- Initial Option Grants:
- 46,000 shares vesting annually over three years.
- 19,166 shares vesting in full on the one-year anniversary of the grant date.
- Future Grants: Automatic annual grants of 23,000 shares on the date of each annual meeting, vesting in full one year later.
- Change in Control: All option grants vest in full upon a change in control.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 65,166 initial option grants.
- Review the Company's Amended and Restated 2014 Equity Incentive Plan for specific vesting acceleration clauses.
- Confirm Dr. Collins' background and potential conflicts of interest via the attached press release (Exhibit 99.1).
- Check subsequent filings for the impact of this appointment on Board committee assignments.